Jessica Stitt
Nessuna posizione attualmente
Storia della carriera di Jessica Stitt
Precedenti posizioni note di Jessica Stitt
Società | Posizione | Inizio | Fine |
---|---|---|---|
GYROSCOPE THERAPEUTICS HOLDINGS PLC | Director of Finance/CFO | 01/03/2021 | 01/04/2022 |
MYOKARDIA, INC. | Corporate Officer/Principal | 01/02/2020 | 01/01/2021 |
THERAVANCE BIOPHARMA, INC. | Public Communications Contact | - | - |
Formazione di Jessica Stitt
St. Anselm College | Undergraduate Degree |
Simmons School of Management | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
Regno Unito | 2 |
Posizioni
Director of Finance/CFO | 1 |
Corporate Officer/Principal | 1 |
Public Communications Contact | 1 |
Settori
Health Technology | 4 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
THERAVANCE BIOPHARMA, INC. | Health Technology |
Aziende private | 2 |
---|---|
MyoKardia, Inc.
MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Gyroscope Therapeutics Holdings Plc
Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Gyroscope Therapeutics Holdings Plc engages in the development of gene therapy beyond rare diseases. It focuses on age-related macular degeneration. The company was founded in 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Jessica Stitt
- Esperienza